Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

[1]  V. Pavone,et al.  COVID-19 and pneumonia: a role for the uPA/uPAR system , 2020, Drug Discovery Today.

[2]  I. Bruce,et al.  Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort , 2019, The Journal of Rheumatology.

[3]  M. Petri,et al.  Systemic lupus erythematosus: Diagnosis and clinical management. , 2019, Journal of autoimmunity.

[4]  Zhancheng Gao,et al.  Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study , 2018, Critical Care.

[5]  M. Schneider.  Pitfalls in lupus. , 2016, Autoimmunity reviews.

[6]  K. Iversen,et al.  Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study , 2016, Emergency Medicine Journal.

[7]  A. Quyyumi,et al.  Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.

[8]  L. Magder,et al.  Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence , 2015, The Journal of Rheumatology.

[9]  J. Wetterö,et al.  Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus , 2015, BMC Musculoskeletal Disorders.

[10]  M. Ekstedt,et al.  Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. , 2015, Translational research : the journal of laboratory and clinical medicine.

[11]  J. Wetterö,et al.  Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity , 2015, The Journal of Rheumatology.

[12]  J. Wetterö,et al.  Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus? , 2015, Clinica chimica acta; international journal of clinical chemistry.

[13]  I. Bruce,et al.  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort , 2014, Annals of the rheumatic diseases.

[14]  F. Tacke,et al.  Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[15]  J. Wetterö,et al.  Association of Serum C‐Reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferon‐α and a C‐Reactive Protein Gene Variant , 2014, Arthritis & rheumatology.

[16]  R. Colman,et al.  High Molecular Weight Kininogen Binds Phosphatidylserine and Opsonizes Urokinase Plasminogen Activator Receptor–Mediated Efferocytosis , 2014, The Journal of Immunology.

[17]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[18]  C. Pisinger,et al.  Risk Factors Associated with Serum Levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator Receptor in a General Population , 2014, Biomarker insights.

[19]  J. Wetterö,et al.  Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. , 2013, Translational research : the journal of laboratory and clinical medicine.

[20]  T. Hansen,et al.  Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. , 2013, International journal of cardiology.

[21]  M. Halushka,et al.  Concise Report , 2022 .

[22]  A. Schutte,et al.  NT-proBNP, C-Reactive Protein and Soluble uPAR in a Bi-Ethnic Male Population: The SAfrEIC Study , 2013, PloS one.

[23]  I. Bruce,et al.  Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort , 2012, Annals of the rheumatic diseases.

[24]  B. Vásárhelyi,et al.  Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission , 2012, Clinical chemistry and laboratory medicine.

[25]  L. Magder,et al.  Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. , 2012, Arthritis and rheumatism.

[26]  C. Trautwein,et al.  Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection , 2012, Journal of clinical gastroenterology.

[27]  D. Rifkin,et al.  Binding of Anti-SSA Antibodies to Apoptotic Fetal Cardiocytes Stimulates Urokinase Plasminogen Activator (uPA)/uPA Receptor-Dependent Activation of TGF-β and Potentiates Fibrosis , 2011, The Journal of Immunology.

[28]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[29]  T. Hansen,et al.  Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. , 2011, Atherosclerosis.

[30]  T. Hansen,et al.  Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population , 2010, Journal of internal medicine.

[31]  J. Buyon,et al.  Role of the Urokinase Plasminogen Activator Receptor in Mediating Impaired Efferocytosis of Anti-SSA/Ro–Bound Apoptotic Cardiocytes: Implications in the Pathogenesis of Congenital Heart Block , 2010, Circulation Research.

[32]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.

[33]  M. Menshikov,et al.  Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis , 2010, Inflammation.

[34]  J. Wetterö,et al.  Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? , 2009, Arthritis and rheumatism.

[35]  Jesper Eugen-Olsen,et al.  suPAR: The Molecular Crystal Ball , 2009, Disease markers.

[36]  G. Schwartz,et al.  Measurement and estimation of GFR in children and adolescents. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[37]  F. Blasi,et al.  Efferocytosis: another function of uPAR. , 2009, Blood.

[38]  E. Abraham,et al.  Participation of the urokinase receptor in neutrophil efferocytosis. , 2009, Blood.

[39]  R. Birge,et al.  The Urokinase Plasminogen Activator Receptor Promotes Efferocytosis of Apoptotic Cells , 2009, The Journal of Biological Chemistry.

[40]  M. Petri,et al.  High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. , 2008, Seminars in arthritis and rheumatism.

[41]  J. Iversen,et al.  Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV‐infected patients receiving highly active antiretroviral therapy , 2008, Journal of medical virology.

[42]  R. L. Nielsen,et al.  The prognostic value of the suPARnostic® ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms , 2007, BMC infectious diseases.

[43]  P. Emery,et al.  The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index. , 2007, Arthritis and rheumatism.

[44]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[45]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. , 2003, Rheumatology.

[46]  L. Alfredsson,et al.  Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases , 2003, Annals of the rheumatic diseases.

[47]  O. Nived,et al.  High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[48]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[49]  N. Brünner,et al.  Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling , 2001, The International journal of biological markers.

[50]  D. Gladman,et al.  Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus , 2001, Lupus.

[51]  N. Brünner,et al.  Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis , 1999, Annals of the rheumatic diseases.

[52]  K. Preissner,et al.  Vitronectin Concentrates Proteolytic Activity on the Cell Surface and Extracellular Matrix by Trapping Soluble Urokinase Receptor-Urokinase Complexes , 1998 .

[53]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[54]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[55]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[56]  H. Johnsen,et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. , 1994, American journal of clinical pathology.

[57]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.